![Pekka Männistö](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Pekka Männistö
Nessuna posizione attualmente
Profilo
Pekka Männistö worked as Co-Chief Executive Officer at Dassiet Oy, Research Director at Orion Pharma Oy, Director at Hermo Pharma Oy, and Principal at the University of Kuopio and the University of Helsinki.
He holds a doctorate degree from the University of Helsinki.
Precedenti posizioni note di Pekka Männistö
Società | Posizione | Fine |
---|---|---|
Dassiet Oy
![]() Dassiet Oy Medical SpecialtiesHealth Technology Onbone Oy develops medical casting and splinting materials for use in the fields of orthopaedics, traumatology and occupational therapy. The company was founded by Petro Antero Kirmo Lahtinen, Antti Pärssinen, Jari Juhani Salo, Matti Eino Olavi Vaheri, and Karri Airola on November 18, 2008 and is headquartered in Oulu, Finland. | Amministratore Delegato | - |
Orion Pharma Oy
![]() Orion Pharma Oy Pharmaceuticals: MajorHealth Technology Orion Pharma Oy provides contract manufacturing services to the pharmaceutical sector. Its services include sterile, solid forms, liquid forms, semi-solid forms, hormone, and anti-cancer production, primary as well as secondary packaging, and testing. The company is headquartered in Espoo, Finland. | Direttore Tecnico/Scientifico/R&S | - |
University of Helsinki | Corporate Officer/Principal | - |
University of Kuopio | Corporate Officer/Principal | - |
Hermo Pharma Oy
![]() Hermo Pharma Oy Pharmaceuticals: MajorHealth Technology Hermo Pharma Ltd. is a biopharmaceutical company which aims to discover and develop cutting-edge therapeutic approaches for currently untreatable medical needs, particularly in the field of neurology. The company's R&D programs are based on scientifically innovative concepts. These concepts are being developed through preclinical and early clinical development phases with the aim gaining partners prior to late clinical development phases and finally marketing. The company was founded in 2008 by professors Mart Saarma, Eero Castrén, Heikki Rauvala and Dr. Henri Huttunen. The company operates in close collaboration with several academic laboratories affiliated with the University of Helsinki. Hermo Pharma Ltd. operates according to the 'virtual business model'. This means the company outsources the majority of business functions outside of its core business areas, while controlling the key technology assets and strategic partnerships with a small but highly capable group of people managing operations. As the company's overheads are kept lower than traditional biopharmaceutical companies much more of its financial resources can be utilized directly to achieve business goals. Hermo Pharma Ltd. is a privately owned, venture capital backed company. Its current investors include Helsinki University Funds and Seed Fund Vera Ltd. | Direttore/Membro del Consiglio | - |
Formazione di Pekka Männistö
University of Helsinki | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 3 |
---|---|
Orion Pharma Oy
![]() Orion Pharma Oy Pharmaceuticals: MajorHealth Technology Orion Pharma Oy provides contract manufacturing services to the pharmaceutical sector. Its services include sterile, solid forms, liquid forms, semi-solid forms, hormone, and anti-cancer production, primary as well as secondary packaging, and testing. The company is headquartered in Espoo, Finland. | Health Technology |
Dassiet Oy
![]() Dassiet Oy Medical SpecialtiesHealth Technology Onbone Oy develops medical casting and splinting materials for use in the fields of orthopaedics, traumatology and occupational therapy. The company was founded by Petro Antero Kirmo Lahtinen, Antti Pärssinen, Jari Juhani Salo, Matti Eino Olavi Vaheri, and Karri Airola on November 18, 2008 and is headquartered in Oulu, Finland. | Health Technology |
Hermo Pharma Oy
![]() Hermo Pharma Oy Pharmaceuticals: MajorHealth Technology Hermo Pharma Ltd. is a biopharmaceutical company which aims to discover and develop cutting-edge therapeutic approaches for currently untreatable medical needs, particularly in the field of neurology. The company's R&D programs are based on scientifically innovative concepts. These concepts are being developed through preclinical and early clinical development phases with the aim gaining partners prior to late clinical development phases and finally marketing. The company was founded in 2008 by professors Mart Saarma, Eero Castrén, Heikki Rauvala and Dr. Henri Huttunen. The company operates in close collaboration with several academic laboratories affiliated with the University of Helsinki. Hermo Pharma Ltd. operates according to the 'virtual business model'. This means the company outsources the majority of business functions outside of its core business areas, while controlling the key technology assets and strategic partnerships with a small but highly capable group of people managing operations. As the company's overheads are kept lower than traditional biopharmaceutical companies much more of its financial resources can be utilized directly to achieve business goals. Hermo Pharma Ltd. is a privately owned, venture capital backed company. Its current investors include Helsinki University Funds and Seed Fund Vera Ltd. | Health Technology |
- Borsa valori
- Insiders
- Pekka Männistö